Sign in

You're signed outSign in or to get full access.

EB

Ensysce Biosciences, Inc. (ENSC)·Q2 2025 Earnings Summary

Executive Summary

  • Initiated pivotal Phase 3 PF614-301 post‑abdominoplasty pain study in July, a major regulatory and commercial milestone; PF614‑MPAR Part 2 fully enrolled and $5.3M NIDA installment received, strengthening non‑dilutive funding .
  • Q2 2025 EPS was $(0.79), a beat vs Wall Street consensus of $(1.015); federal grant revenues were $1.37M, a beat vs $0.67M consensus, narrowing net loss YoY and QoQ .
  • Cash and equivalents were $2.21M at quarter‑end, down from $3.05M in Q1; operating loss margin improved QoQ as grant revenue rose with MPAR clinical activity .
  • Near‑term stock catalysts: PF614 Phase 3 execution/early site activation updates, PF614‑MPAR‑102 Part 2 data readout and Part 3 progress, and any financing/partnership updates to extend runway .

What Went Well and What Went Wrong

  • What Went Well

    • “Initiation of our pivotal Phase 3 trial for PF614 marks a major achievement…a critical step toward achieving our clinical and commercial strategy,” positioning PF614 for NDA in severe post‑surgical pain .
    • PF614‑MPAR‑102 Part 2 fully enrolled; Breakthrough Therapy designation continues to accelerate development with NIDA support .
    • Q2 grants revenue rose to $1.37M (vs $0.18M YoY), contributing to narrower net loss of $1.73M (vs $1.97M YoY) .

  • What Went Wrong

    • Cash declined to $2.21M at quarter‑end, highlighting near‑term liquidity risk as R&D expense rose to $1.92M on MPAR and pre/clinical activities .
    • No quantitative guidance was provided (revenue/margins), limiting visibility; management reiterates losses expected for foreseeable future as clinical‑stage biotech .
    • Dependence on grant timing created variability; other income remains minimal ($16,998), underscoring need for financing or partnership milestones .

Financial Results

MetricQ2 2024Q1 2025Q2 2025
Federal Grants ($USD)$181,797 $1,319,772 $1,371,438
Total Operating Expenses ($USD)$2,137,239 $3,287,284 $3,121,953
Loss from Operations ($USD)$(1,955,442) $(1,967,512) $(1,750,515)
Net Loss Attributable to Common Stockholders ($USD)$(1,967,793) $(1,945,573) $(1,733,351)
Diluted EPS ($)$(3.35) $(1.39) $(0.79)
Net Loss Margin % (Net Loss / Grants)(1,082.0%) (147.4%) (126.3%)
Operating Loss Margin % (Op Loss / Grants)(1,076.0%) (149.1%) (127.7%)
Balance Sheet / Cash Flow KPIsQ4 2024Q1 2025Q2 2025
Cash & Equivalents ($USD)$3,502,077 $3,052,491 $2,211,575
Total Liabilities ($USD)$2,217,293 $1,891,356 $2,514,043
Stockholders’ Equity ($USD)$3,379,939 $2,720,518 $3,060,412
Estimates vs Actuals (Q2 2025)Consensus*Actual
EPS ($)$(1.015)*$(0.79)
Federal Grants Revenue ($USD)$673,080*$1,371,438

Values retrieved from S&P Global.*

Segment breakdown: Not applicable; no commercial product revenues reported .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Revenue/Federal GrantsFY/Q3‑Q4 2025None providedNone providedMaintained (no guidance)
R&D ExpenseFY/Q3‑Q4 2025None providedExpect continued losses as R&D progressesMaintained qualitative view
PF614 Phase 32H 2025Initiation targeted mid‑2025Initiated July 2025Raised (milestone achieved)
PF614‑MPAR‑1022H 2025Progressing Parts 2/3Part 2 fully enrolled; Part 3 continuing through year‑endOn track
OUD PF90012025+IND‑enabling plannedNotice of Allowance for patent; advancing non‑clinicalStrengthened IP, program advancing

Earnings Call Themes & Trends

No earnings call/transcript available for Q2 2025; themes derived from Q4 2024 and Q1–Q2 2025 earnings releases.

TopicPrevious Mentions (Q4 2024)Previous Mentions (Q1 2025)Current Period (Q2 2025)Trend
PF614 Phase 3Protocol submitted; site selection underway Working toward mid‑year initiation Phase 3 initiated July with Rho CRO Advancing to pivotal execution
PF614‑MPAR overdose protection102 trial initiated; positive interim data incl. 100 mg dose Part 1 completed; overdose protection confirmed Part 2 fully enrolled; awaiting data; Part 3 ongoing Continued de‑risking
OUD PF9001Lead selected; HEAL grant supports non‑clinical Notice of Allowance announced; IP expansion Notice of Allowance confirmed; advancing toward IND‑enabling Strengthening IP and progression
Funding/Grants (NIDA)$14M multi‑year award for MPAR Ongoing MPAR grant support $5.3M installment received in Q2 Stable non‑dilutive support
Regulatory statusBTD for PF614‑MPAR highlighted BTD reiterated BTD reiterated; Phase 3 start signals pathway Regulatory momentum

Management Commentary

  • “The initiation of our pivotal Phase 3 trial for PF614 marks a major achievement…This study is designed to validate PF614’s ability to deliver…superior pain relief…with built‑in abuse deterrence” — CEO Dr. Lynn Kirkpatrick .
  • “Fully enrolling Part 2 of our PF614‑MPAR‑102 study…With continued financial support from NIDA and the FDA’s Breakthrough Therapy designation, we are accelerating development of what could be a game‑changing solution” — CEO .
  • Q1 context: “Part 1 of our PF614‑MPAR‑102 clinical study…confirmed protection from the risk of overdose when PF614‑MPAR at any dose level is consumed accidentally or deliberately” — CEO .

Q&A Highlights

No Q&A available; no earnings call transcript found for Q2 2025 [ListDocuments result: none]. Clarifications: management reiterated expectation of continued losses as clinical programs advance and highlighted reliance on grant timing .

Estimates Context

  • Q2 2025 beat: EPS $(0.79) vs $(1.015); federal grant revenue $1.37M vs $0.67M, driven by increased clinical activities under MPAR grant and Phase 3 readiness costs .
  • Limited coverage: EPS and revenue estimates had 2 contributors for Q2; monitor estimate dispersion as PF614 Phase 3 progresses and MPAR‑102 data emerges.*
    Values retrieved from S&P Global.*

Key Takeaways for Investors

  • Phase 3 PF614 initiation is a material de‑risking step and potential stock catalyst; track enrollment pace, site activation, and any interim operational updates .
  • PF614‑MPAR‑102 Part 2 completion sets up food‑effect data; Part 3 continuation indicates sustained program momentum under BTD and NIDA support .
  • Q2 delivered an EPS and revenue beat vs consensus*, but liquidity remains tight with $2.21M cash; expect financing/partnership updates near‑term to extend runway .
  • Operating loss margin improved QoQ as grant revenue increased; continued R&D intensity likely keeps losses elevated until regulatory or commercial inflection .
  • Watch for regulatory interactions (FDA feedback on PF614‑301 operational execution) and IP expansion around PF9001 to support longer‑term OUD thesis .
  • Risk factors: grant timing variability, financing/dilution, and potential Nasdaq compliance issues referenced in forward‑looking statements; position sizing should reflect binary clinical milestones .

Additional relevant press releases:

  • PF614 Phase 3 initiation (July 16, 2025) .
  • PF614‑MPAR‑102 Part 2 full enrollment (June 24, 2025) .